3
Announcements
Trials
Browse
Landscape
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Thyroid Nodule
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Spinal Cord Compression
1
Sarcoma
1
Prostatic Neoplasms
1
Papillomavirus Infections
1
Neoplasms, Unknown Primary
1
Melanoma
1
Gastrointestinal Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Adenocarcinoma
1
Acquired Immunodeficiency Syndrome
1
Interventions
Magnetic Resonance Spectroscopy
56
enzalutamide
44
Specimen Handling
37
apalutamide
35
Androgen Antagonists
35
Abiraterone Acetate
29
Prednisone
27
Radiosurgery
26
darolutamide
25
Docetaxel
23
Pluvicto
22
abiraterone
21
Radiotherapy
21
Leuprolide
20
Biopsy
16
relugolix
14
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
14
gallium 68 PSMA-11
12
Triptorelin Pamoate
12
Surveys and Questionnaires
12
Radiation
12
Gonadotropin-Releasing Hormone
12
X-Rays
11
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
10
cabazitaxel
9
bicalutamide
9
Standard of Care
9
Nivolumab
9
Goserelin
9
Carboplatin
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Transurethral Resection of Prostate
×
90 days
×
Clear all
NCT07237399
2026-05-13
TA-P-OLIM
University Hospital, Ghent
Withdrawn